fr 139317 has been researched along with puromycin aminonucleoside in 1 studies
| Studies (fr 139317) | Trials (fr 139317) | Recent Studies (post-2010) (fr 139317) | Studies (puromycin aminonucleoside) | Trials (puromycin aminonucleoside) | Recent Studies (post-2010) (puromycin aminonucleoside) |
|---|---|---|---|---|---|
| 219 | 0 | 8 | 874 | 3 | 144 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebihara, I; Koide, H; Nakamura, T; Tomino, Y | 1 |
1 other study(ies) available for fr 139317 and puromycin aminonucleoside
| Article | Year |
|---|---|
Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Azepines; Enalapril; Endothelin Receptor Antagonists; Endothelin-1; Extracellular Matrix; Gelatinases; Glycoproteins; Indoles; Kidney Glomerulus; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Nephrosis; Protease Inhibitors; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger; Tissue Inhibitor of Metalloproteinases | 1997 |